Background: Increasing use of medicinal herbs as nutritional supplements and tradi-
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| INTRODUC TI ON
Management of chronic diseases is burdensome to patients (Eton et al., 2013; Ørtenblad, Meillier, & Jønsson, 2017 ) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self-medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009) , and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008) . The perceived believe of cure and safety of these agents makes ambulatory patients take them without due recourse to their physician (Mehta, Gardiner, Phillips, & McCarthy, 2008; Zhang, Onakpoya, Posadzki, & Eddouks, 2015) .
In various settings, about 40%-57% of patients fail to disclose herbs used concomitantly with their medications to the physician (Robinson & McGrail, 2004; Fakeye, Tijani, & Adebisi, 2008; Kennedy, Wang, & Wu, 2008) . Some of these herbs especially in sub-Saharan Africa, India, and in some other parts of the world are consumed as seasoning agents (garlic-Allium sativum), vegetables (Gongronema latifolium and Moringa oleifera), and as edible fruits and seeds (Musa sapientum, Mangifera indica, and Tetracarpidium conophorum) . Patients who are on medications and consumes these medicinal herbs may not be aware of potential herb-drug interactions (HDIs) that may occur. Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub-Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014) .
Sometimes, in the treatment of these diseases, herbs may be used singly or in combination and prepared as dried powder or decoction. There are many examples of such practice. For example, for rheumatism, bark of Picralima nitida, leaves of Allium ascalonicum, Calliandra portoricensis, and Xylopia aethiopica are grounded, cooked, and 15 ml of the mixture is mixed with corn pap and taken once daily (Olorunnisola, Adetutu, & Afolayan, 2015) . For anemia, a mixture of the bark of Mangifera indica and fruits of Aframomum melequeta is dried and powdered with one tablespoonful administered daily (Gbadamosi, Moody, & OYekini, 2012) . A decoction of dried bark of Alstonia boonei is also taken two-to three times daily by diabetic patients to lower blood glucose (Adotey, Adukpo, Opoku Boahen, & Armah, 2012) .
Many diseases are usually managed or treated with conventional medicines which are mostly metabolized by cytochrome P450 (CYP) isoenzymes (Rendic & Guengerich, 2014) . These isoenzymes are responsible for the metabolism of over 70% of prescription and over-the-counter medications (Rendic & Guengerich, 2014) . Concomitantly administered drug may modulate these CYP isoenzymes activities leading to clinically significant drug-drug interactions. Such interaction may result in serious adverse drug reactions requiring hospitalization, especially drugs with narrow therapeutic index such as carbamazepine, theophylline, digoxin warfarin, and phenytoin (Greenblatt & von Moltke, 2005; Perucca, 2006; de Leon, 2007; Patel, Rana, Suthar, Malhotra, & Patel, 2014) . It is thus rational to expect herbs to also elicit similar HDIs via modulation of cytochrome P450 isoenzymes when concomitantly administered with conventional drugs.
Herbs contain bioactive secondary metabolites such as anthocyanins, flavonoid, tannins, saponins, alkaloids, and cardenolides, some of which have been shown to inhibit the activity of CYP isoenzymes (Henderson, Miranda, Stevens, Deinzer, & Buhler, 2000; Dreiseitel et al., 2008; Kimura, Ito, Ohnishi, & Hatano, 2010; Sand et al., 2010) .
Several studies have documented the occurrence of serious adverse events as a result of concurrent administration of herbs and drugs. Such interactions included bleeding experienced with coadministration of Allium sativum and nonsteroidal anti-inflammatory drugs (Fugh-Berman, 2000) , manic episode with Panax ginseng and phenelzine (Fugh-Berman, 2000) , and fatal seizure with concomitant administration of Ginkgo biloba and valproate (Kupiec & Raj, 2005) .
Several herbs such as St. John's wort, grapefruit juice, Ginkgo biloba, black pepper, and Echinacea are known inhibitors of CYP 2C9, 2C19, 2E1, and 3A4 (Wang et al., 2001; Gorski et al., 2004; Mohutsky, Anderson, Miller, & Elmer, 2006; Sukkasem & Jarukamjorn, 2016) .
Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.
The possibility of occurrence of HDIs when herbs are consumed as seasoning agents, vegetables, fruits and as herbal medicines with conventional drugs informed this study. Since inhibition of CYP isoenzymes is the first step toward elucidating potential HDIs, this study evaluated nine widely used tropical medicinal herbs with a view to identifying those with potentials for CYP-metabolismmediated HDIs.
Some of the herbs considered in this study have also been shown to inhibit CYP isoenzymes. Allium sativum inhibits CYP 2C9, 2C19, 2D6, 3A4/5, and 3A7 (Foster et al., 2001; Greenblatt, LeighPemberton, & von Moltke, 2006; Engdal & Nilsen, 2009) ; Moringa oleifera-CYP 1A2, 3A4, and 2D6 (Monera, Wolfe, Maponga, Benet, & Guglielmo, 2008; Taesotikul, Navinpipatana, & Tassaneeyakul, 2010; Ahmmed et al., 2015; Awortwe, 2015) ; Musa sapientum-CYP 1A2 and 3A11 (Chatuphonprasert & Jarukamjorn, 2012) while Mangifera indica has been shown to inhibit CYP 1A2, 2C9, 2C19, 2D6, 3A4, and 3A11 (Chatuphonprasert & Jarukamjorn, 2012) . In the above studies, different enzyme sources, probe substrates, and extraction methods were employed in evaluating one to five CYP isoenzyme inhibition profiles of the stated herbs which do not represent the full complement of major human CYP isoenzymes. The present study improved on this by mimicking local methods of preparation of plant extracts, used pooled human liver microsomes containing eight major CYP isoenzymes responsible for over 70% metabolism of drugs (Rendic & Guengerich, 2014) , and nine probe substrates with N-in-one cocktail method to profile the inhibitory potentials of the herbs on CYP isoenzymes.
| MATERIAL S AND ME THODS

| Preparation of aqueous extracts of plant parts
Nine medicinal herbs widely used in the tropics for the management of chronic diseases such as hypertension, diabetes, dyslipidemia, chronic kidney disease were selected for this study with the plant parts used and listed in Table 1 
| Chemicals
| CYP inhibition experiments
Human liver microsomes were obtained from a pool of liver samples from 25 male and female donors and contain 20 mg protein/ ml (Lot No: 99268 from BD Biosciences Labware, Bedford, MA). This was used for the metabolite profiling and CYP inhibition study. N-inone approach (cocktail-approach) for elucidating inhibition toward CYP-specific model reactions was conducted with minor changes as described in earlier studies (Turpeinen, Jouko, Jorma, & Olavi, 2005; Tolonen, Petsalo, Turpeinen, Uusitalo, & Pelkonen, 2007; Showande, Fakeye, Ari, & Hokkanen, 2013) . Briefly, the incubation mixture was made up of 0.3 mg microsomal protein/ml, 0.1 M phosphate buffer (pH 7.4), 1 mM NADPH, and nine probe substrates representing the major drug-metabolizing CYPs. The specific probe substrate used for each CYP isoenzymes studied and the respective final concentration in the incubation mixture were as follows: acetaminophen (CYP1A2, Table S1 ), CYP isoenzymes inhibited, and concentration used in the N-in-one assay are as reported in the validated methods (Turpeinen et al., 2005; Tolonen et al., 2007; Showande et al., 2013) . Spiked standard samples were not used for quantification of probe metabolites, but quantification based on relative peak areas was used (solvent control = 100%).
| Liquid chromatography-mass spectrometry conditions
The analysis of probe metabolites from CYP-specific marker reactions was conducted with a LC/MS/MS method modified from earlier works (Turpeinen et al., 2005; Tolonen et al., 2007) and also reported by (Showande et al., 2013) . Briefly, a Waters Acquity UPLC system (Waters Corp., Milford, MA) was used together with a Waters HSS C18 column (2.1 mm × 50 mm; 1.8 μm particle size) and an online filter at 35°C. The injection volume was 4 μl, and UPLC eluents were aqueous 0.1% acetic acid (pH 3.2, A) and acetonitrile (B). The gradient elution from 2%-65%-95% B was applied in 0-2.5-3.5 min, followed by column equilibration, giving a total time of 4.5 min/injection. The eluent flow rate was 0.5 ml/min. Data were acquired using a Thermo TSQ Endura triple quadrupole MS. Multiple reaction monitoring (MRM) mode using positive ion mode. For all compounds, the spray voltage was 4500 V, vaporizer temperature and transfer tube temperature were 400°C and 350°C, respectively. The CID argon pressure was set to 2.0 mTorr. The MRM transitions were as previously described (Tolonen et al., 2007; Turpeinen et al., 2005) . 
| Classification of inhibitory potential of herb extract
The herb extracts were classified as potent, moderate, or weak inhibitor depending on the IC 50 obtained (Gwaza et al., 2009; Sevior et al., 2010; Kong et al., 2011) . Potent inhibitors have IC 50 ≤ 10 μg/ ml, moderate inhibitors have IC 50 >10 μg/ml -≤100 μg/ml, and weak inhibitors have IC 50 > 100 μg/ml. In this study, significant in vitro inhibition is considered as IC 50 < 100 μg/ml (Sevior et al., 2010) .
| Prediction of possibility of in vivo herb-drug interactions from in vitro data
Determination of molar IC 50 values in herbal extracts is challenging thus representing the in vitro IC 50 values in Liter/dose as described by Strandell, Neil, and Carlin (2004) gives insight into possibility of in vivo inhibition. The volume to which an estimated human unit dose of the aqueous extract of each herb should be diluted in vivo to give similar in vitro inhibitory concentration for each CYP isoenzymes was calculated using the equation (2) 
| RE SULTS
Aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs did not produce significant inhibition of the CYP isoenzymes investigated at any of the concentrations used, IC 50 > 1000 μg/ml. But Gongronema latifolium, Bauhinia monandra, and Moringa oleifera leave extracts showed weak inhibition of CYP1A2 with IC 50 > 100 μg/ml (Table 2) . Alstonia boonei stem bark aqueous extract also weakly inhibited CYP2C9, CYP2C19, and CYP3A4 but moderately inhibited CYP2D6 ( Table 2 ). The inhibition of CYP2D6 was dose-dependent inhibition (Figure 1a ).
Aqueous extract of Mangifera indica stem bark showed weak inhibitory activities on CYP2A6, CYP2C19 and CYP3A4 but exhibited moderate inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 (Table 2 ). The plant extract displayed 100% inhibition of all the CYP isoenzymes investigated at a dose of 1000 μg/ml (Figure 1b) .
Picralima nitida seeds aqueous extract demonstrated potent inhibitory activity on CYP2D6, with IC 50 of 1.19 μg/ml, but moderately inhibited CYP2C19 and CYP3A4 (Table 2 ). These inhibitory activities were dose-dependent (Figure 1c 
| D ISCUSS I ON
Drug-drug interaction or herb-drug interaction studies could be conducted as in vitro or in vivo studies, case reports, and human studies using human subjects. In vitro herb-drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb-drug interactions and to help design appropriate in vivo herb-drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013 IC 50 value in bold represent significant inhibition of CYP isoenzymes with IC 50 < 100 μg/ml, (ND) Not determined. Metabolites monitored the following: acetaminophen (ACET), 7-hydroxycoumarin (7-OH-COU), hydroxybupropion (OH-BUP), hydroxyrepaglinide (OH-REPA), 4-hydroxydiclofenac (OH-DICL), 5-hydroxyomeprazole (5-OH-OME), desmethylomeprazole (DeM-OME), Dextrorphan (OdeM-DEX), 3-hydroxyomeprazole (3-OH-OME), omeprazole sulfone (SO2-OME), 6β-hydroxytestosterone (6β-OH-TES), 1-hydroxymidazolam (1-OH-MDZ).
inhibitor, or inducer of metabolizing enzymes (Phase I or Phase II enzymes), transporter proteins (P-gp, BCRP, OATP1B1, OATP1B3, OAT, OCT, and MATE) and also to evaluate whether the metabo- 2D6, 3A4/5, and 3A7 by different types of Allium sativum. In another study, only two water-soluble components of aged garlic were able to moderately inhibit CYP3A4 (Greenblatt et al., 2006) . Also, aged garlic extract produced no significant inhibition of CYP isoenzymes in humans (Markowitz, 2003) . Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources. In this study, aqueous extract of oven-dried Allium sativum bulbs was used.
There is no conclusive report of a significant in vitro inhibition of CYP isoforms by Allium sativum both from this study and others. Thus, the possibility of Allium sativum aqueous extract in vivo HDIs mediated by CYP isoenzymes may be remote as supported by our study and that of Markowitz (2003) .
Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9. This result is similar to the inhibition of CYP1A2 by ethanolic and aqueous extracts of Moringa oleifera leaves reported earlier (Taesotikul et al., 2010) . Other studies reported inhibition of CYP3A4 (Ahmmed et al., 2015; Awortwe, 2015; Monera et al., 2008) and CYP2D6 by aqueous and/or ethanolic ex- values in L/ dose converted from μg/mL for CYP1A2 and CYP2C9
were 3.12 L/dose and 1.43 L/dose, respectively. These are higher than 0.88 L/dose estimated by Strandell et al. (2004) as the minimum required to elicit further investigation of in vivo inhibitory activity of the plant extract on CYP isoenzyme. However, in vivo study in human showed that M. oleifera did not affect the pharmacokinetic parameters of Nevirapine, a substrate of CYP2C9, CYP2D6, and CYP3A5 (Monera-Penduka et al., 2017) . Nonetheless, couse
of Moringa oleifera leave extract with substrates of CYP1A2 and CYP2C9 should be further investigated for possibility of in vivo inhibition of these isoenzymes which may affect therapeutic outcome of coadministered medication.
Stem bark aqueous extract of Mangifera indica moderately inhibited CYP1A2, CYP2B6, CYP2C8, CYP2C9, and CYP2D6 (IC 50 < 100 μg/ml) while others CYPs such as 2A6, 2C19, and 3A4
were weakly inhibited (IC 50 > 100 μg/ml) by the extract. These results are similar to the inhibition of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 by aqueous extract of Mangifera indica stem bark using human liver microsomes and primary hepatocytes reported by Rodeiro et al. (2008 Rodeiro et al. ( , 2013 . Mangifera indica fruit and stem bark extract are commonly used by patients because of the folkloric claims and documented pharmacological activities in ameliorating the signs and symptoms of diabetes, treatment of malaria fever, menorrhagia, hypertension, and hypercholesterolemia (Ezuruike & Prieto, 2014; Awortwe, 2015; Gururaja et al., 2017) . Most of the drugs used in the treatment and management of these diseases are metabolized by the major CYP isoenzymes, namely CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 (Ogu & Maxa, 2000; Lynch & Price, 2007) .
Concomitant use of aqueous extract of Mangifera indica stem bark with substrates of these CYP isoenzymes especially CYP2C8, CYP2C9, and CYP3A4 may predispose the patient to clinically significant HDIs. Coadministration of Mangifera indica fruit with warfarin was found to increase the international normalize ratio (INR) significantly by 38% in thirteen male patients after 2-30 days of consumption (Monterrey-Rodríguez, Feliú, & Rivera-Miranda, 2002 ).
This interaction was suggested to be due to the inhibitory effect of Vitamin A, contained in the fruit, on CYP2C19-an enzyme responsible for the metabolism (7-hydroxylation) of the warfarin R-isomer (Yamazaki, 1999) . Aqueous extract of Mangifera indica bark also showed a weak inhibitory effect on CYP2C19 in the present study. Earlier studies by Gurley et al. (2005 Gurley et al. ( , 2006 Gurley et al. ( , 2008 confirmed these predictions. Strandell et al. (2004) predicted the likelihood of potent in vivo inhibition of CYP3A4 by hypericum (St John's Wort) preparations; this also confirmed the report of Markowitz et al. (2000) .
Currently, no study seems to be available on the in vitro or in vivo inhibitory activity of six of the herbs studied-aqueous extracts of Picralima nitida seeds, Gongronema latifolium leaves, Tetracarpidium conophorum seeds, Musa sapientum unripe fruits, Bauhinia monandra leaves, and Alstonia boonei stem bark. Our study may be the first report of the in vitro inhibitory potential of these herb extracts.
Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC 50 values are greater than 0.88 L/dose despite the weak in vitro inhibitory potential on these isoenzymes. Aside from its medicinal properties, Gongronema latifolium is a popular delicacy in African cuisine (Akinsanmi & Nwanna, 2015; Nwanna et al., 2016) . This may increase the possibility of HDIs if drugs are taken after the consumption of a meal containing Gongronema latifolium vegetable. Aqueous extract of Bauhinia monandra leaves is likely to exhibit in vivo inhibition on CYP1A2, CYP2C8, and 3A4 with converted IC 50 > 3.0 L/dose unit.
One of the problems of studying herb-drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb. Because of this, it is difficult to quantify the molar IC 50 value of these herbs; thus, HDIs (Strandell et al., 2004) .
Picralima nitida seem to be the most potent of the nine herbs studied with IC 50 < 100 μg/ml for CYP2C19 and CYP3A4 and IC 50 < 10 μg/ml for CYP2D6. The IC 50 value converted into L/dose for CYP2C19, CYP3A4, and CYP2D6 far exceeded the 0.88 L/ dose unit cutoff point by Strandell et al. (2004) . With these val- 
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